|Ms. Monica Wallter||Sr. Advisor||1.87M||N/A||1956|
|Mr. Anders Mansson||Chief Exec. Officer||N/A||N/A||1967|
|Ms. Jenni Bjornulfson||CFO & Head of IR||N/A||N/A||1971|
|Mr. Matthew Lindon||Chief Scientific Officer||N/A||N/A||1973|
|Dr. Johan Harmenberg M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1954|
|Ms. Annette Moldrup||Chief Bus. Devel. Officer||N/A||N/A||1961|
|Ms. Kia Bengtsson||Head of Clinical Devel.||N/A||N/A||1969|
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.
LIDDS AB (publ)’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.